Company intelligence / Profile preview

Regensight

Ownership: Private
Development stage: Commercial

Overview

Regensight has developed a highly sophisticated UV-A medical device ("C4V CHROMO4VIS") that enables painless, incision-free surgical correction of common visual disorders such as keratoconus and corneal ectasia. The company leverages theranostic approaches to personalize treatment. Clinical results are not detailed on the public site but the focus is on providing a new standard of care for these indications[1][2].

Therapeutic areas: Ophthalmology
Modalities: DeviceTheranostics technology (combining diagnostics and therapy)
Industry: Therapeutic Medical Devices

Drug pipeline

2 assets

TheraCXL

Development

Indications: Keratoconus

1 more asset in the full pipeline.

Request access →

Partnerships

Not specified publicly.

Beyond the preview

Go deeper on Regensight.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Regensight.

Explore the full profile